The Current Status and Research Progress of Antiviral Therapy in HCV-Associated Lymphoma --Review.
10.19746/j.cnki.issn.1009-2137.2021.06.052
- Author:
Xiao-Hong SUN
1
;
Shun WAN
2
;
Zi-Jian LI
3
Author Information
1. The First Clinical Medical College of Lanzhou University；Lanzhou 730000,Gansu Province, China.
2. The Second Clinical Medical College of Lanzhou University；Lanzhou 730000,Gansu Province, China.
3. Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000,Gansu Province, China,E-mail: ldyy_lizj@lzu.edu.cn.
- Publication Type:Review
- MeSH:
Antiviral Agents/therapeutic use*;
Hepacivirus;
Hepatitis C/drug therapy*;
Hepatitis C, Chronic/drug therapy*;
Humans;
Lymphoma, B-Cell, Marginal Zone/drug therapy*;
Lymphoma, Large B-Cell, Diffuse/drug therapy*
- From:
Journal of Experimental Hematology
2021;29(6):1987-1990
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease. HCV is not only related to hepatic malignancies but may also promote lymphoid neoplasms. Currently, research has confirmed HCV-related lymphoma, including marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma (BL). Many types of research have shown that antiviral therapy can improve or even remission several HCV-related lymphomas. The direct-acting antiviral agents (DAAs) (such as NS5A protease inhibitors, NS4/4A protease inhibitors and viral polymerase inhibitors) have shown clinical advantages of high efficacy and low side effects for both virus elimination and tumor regression in several HCV-related lymphomas, which may make the selected HCV-related lymphoma patients treated without chemotherapy. In this review the research progress and development direction of antiviral therapy in treating HCV-related lymphoma has summarized briefly.
